Nevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) announced that D. Keith Grossman, Chairman and CEO, will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 25, 2021, at 1:30 PM ET / 10:30 AM PT. The event will be accessible via a live webcast on Nevro's website, where an archived recording will also be available.

Nevro, based in Redwood City, California, specializes in innovative solutions for chronic pain treatment, particularly through its proprietary HF10 therapy, proven to reduce or eliminate opioids in over 65% of patients.

REDWOOD CITY, Calif., Feb. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Thursday, February 25, 2021 at 1:30 pm Eastern Time / 10:30 am Pacific Time.

A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247 | julie.dewey@nevro.com 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-present-at-citis-2021-healthcare-services-medtech-tools--hcit-virtual-conference-301218712.html

SOURCE Nevro Corp.

FAQ

When is Nevro presenting at Citi's virtual conference?

Nevro will present at Citi's virtual conference on February 25, 2021, at 1:30 PM ET.

Who is presenting for Nevro at the conference?

D. Keith Grossman, Nevro's Chairman, CEO, and President, will present at the conference.

Where can I watch the Nevro conference presentation?

The presentation will be available via live webcast on Nevro's website.

What is the focus of Nevro's presentation?

Nevro's presentation will focus on innovative solutions for chronic pain treatment.

What is the significance of HF10 therapy mentioned by Nevro?

HF10 therapy is notable for its effectiveness in reducing or eliminating opioids in over 65% of patients.